Slide Insurance Holdings, Inc. (SLDE) closed the last trading session at $18.21, gaining 11.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $22.8 indicates a 25.2% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $2.05. While the lowest estimate of $21.00 indicates a 15.3% increase from the current price level, the most opti ...

Biodesix, Inc. (BDSX) closed the last trading session at $7.83, gaining 3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $33.33 indicates a 325.7% upside potential.The average comprises three short-term price targets ranging from a low of $20.00 to a high of $40.00, with a standard deviation of $11.55. While the lowest estimate indicates an increase of 155.4% from the current pri ...

Core Viewpoint - TAL Education (TAL) has shown a 4% gain over the past four weeks, with a mean price target of $14.3 indicating a potential upside of 25.2% from the current price of $11.42 [1] Price Targets - The average price target consists of seven estimates ranging from a low of $11.54 to a high of $16.85, with a standard deviation of $1.83, suggesting variability in analyst predictions [2] - The lowest estimate indicates a modest increase of 1.1%, while the highest suggests a significant upside of 47.6% [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are optimistic about TAL's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - The Zacks Consensus Estimate for the current year has increased by 52.1% over the past month, with three estimates revised upward and no negative revisions [12] - TAL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Passage Bio, Inc. (PASG) shows significant potential for upside, with a mean price target of $59.25 indicating a 731% increase from its current trading price of $7.13 [1] Price Targets and Estimates - The average price target for PASG ranges from a low of $10.00 to a high of $120.00, with a standard deviation of $46.71, suggesting a high variability in analyst estimates [2] - The lowest estimate indicates a potential increase of 40.3%, while the most optimistic estimate suggests a 1583% upside [2] - Analysts' consensus on price targets is often questioned, as they may not accurately reflect future stock prices [3][7] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding PASG's ability to report better earnings than previously predicted supports the view of potential upside [4] - The Zacks Consensus Estimate for the current year has increased by 30.3% over the past month, with two estimates revised higher and no negative revisions [12] - PASG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Implications of Price Movement - While the consensus price target may not be a reliable indicator of potential gains, the direction implied by these targets appears to be a useful guide for further research [14]